title: Long-term control of HIV replication with dolutegravir and pegylated interferon alpha-2a in an HIV-infected patient with sixtuple-class resistance.
authors.affiliation: aHIV Unit, Internal Medicine Service bNational Hemophilia Center, Sheba Medical Center, Israel cMicrobiology Service, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.
authors.forename: M Luisa
authors.initials: ML
authors.lastname: Montes
authors.forename: Jonathan
authors.initials: J
authors.lastname: Schapiro
authors.forename: Ignacio
authors.initials: I
authors.lastname: Pérez-Valero
authors.forename: Silvia
authors.initials: S
authors.lastname: García-Bujalance
authors.forename: José R
authors.initials: JR
authors.lastname: Arribas
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D024921:Drug Resistance, Multiple, Viral; D004359:Drug Therapy, Combination / Q000379:methods; D006678:HIV / Q000187:drug effects; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D006575:Heterocyclic Compounds, 3-Ring / Q000627:therapeutic use*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010078:Oxazines; D010879:Piperazines; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011728:Pyridones; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins / Q000627:therapeutic use; D016879:Salvage Therapy / Q000379:methods; D016896:Treatment Outcome; D019562:Viral Load; D000099226:Dolutegravir
chemical_list: D019380:Anti-HIV Agents; D006575:Heterocyclic Compounds, 3-Ring; D016898:Interferon-alpha; D010078:Oxazines; D010879:Piperazines; D011092:Polyethylene Glycols; D011728:Pyridones; D012367:RNA, Viral; D011994:Recombinant Proteins; D000099226:Dolutegravir; C100416:peginterferon alfa-2a